ATA107397A - Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons - Google Patents

Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons

Info

Publication number
ATA107397A
ATA107397A AT107397A AT107397A ATA107397A AT A107397 A ATA107397 A AT A107397A AT 107397 A AT107397 A AT 107397A AT 107397 A AT107397 A AT 107397A AT A107397 A ATA107397 A AT A107397A
Authority
AT
Austria
Prior art keywords
cell clone
serum
protein
obtaining
free medium
Prior art date
Application number
AT107397A
Other languages
English (en)
Other versions
AT407255B (de
Inventor
Manfred Reiter
Wolfgang Mundt
Friedrich Dorner
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3506017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATA107397(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AT0107397A priority Critical patent/AT407255B/de
Application filed by Immuno Ag filed Critical Immuno Ag
Priority to US09/100,253 priority patent/US6100061A/en
Priority to US09/324,612 priority patent/US6475725B1/en
Publication of ATA107397A publication Critical patent/ATA107397A/de
Application granted granted Critical
Publication of AT407255B publication Critical patent/AT407255B/de
Priority to US10/170,661 priority patent/US6936441B2/en
Priority to US11/123,362 priority patent/US7094574B2/en
Priority to US11/482,504 priority patent/US20070161079A1/en
Priority to US12/488,441 priority patent/US20090258391A1/en
Priority to US12/488,465 priority patent/US8080414B2/en
Priority to US12/778,776 priority patent/US8084251B2/en
Priority to US12/848,897 priority patent/US8084252B2/en
Priority to US12/986,111 priority patent/US8329465B2/en
Priority to US14/567,942 priority patent/USRE46745E1/en
Priority to US15/203,558 priority patent/USRE46860E1/en
Priority to US15/203,550 priority patent/USRE46897E1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0043—Medium free of human- or animal-derived components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/76—Undefined extracts from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00—Microcarriers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT0107397A 1997-06-20 1997-06-20 Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons AT407255B (de)

Priority Applications (14)

Application Number Priority Date Filing Date Title
AT0107397A AT407255B (de) 1997-06-20 1997-06-20 Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US09/100,253 US6100061A (en) 1997-06-20 1998-06-19 Recombinant cell clone having increased stability in serum- and protein-free medium and a method of recovering the stable cell clone and the production of recombinant proteins by using a stable cell clone
US09/324,612 US6475725B1 (en) 1997-06-20 1999-06-02 Recombinant cell clones having increased stability and methods of making and using the same
US10/170,661 US6936441B2 (en) 1997-06-20 2002-06-12 Recombinant cell clones having increased stability and methods of making and using the same
US11/123,362 US7094574B2 (en) 1997-06-20 2005-05-06 Recombinant cell clones having increased stability and methods of making and using the same
US11/482,504 US20070161079A1 (en) 1997-06-20 2006-07-07 Recombinant cell clones having increased stability and methods of making and using the same
US12/488,441 US20090258391A1 (en) 1997-06-20 2009-06-19 Recombinant cell clones having increased stability and methods of making and using same
US12/488,465 US8080414B2 (en) 1997-06-20 2009-06-19 Recombinant cell clones having increased stability and methods of making and using the same
US12/778,776 US8084251B2 (en) 1997-06-20 2010-05-12 Recombinant cell clones having increased stability and methods of making and using the same
US12/848,897 US8084252B2 (en) 1997-06-20 2010-08-02 Recombinant cell clones having increased stability and methods of making and using the same
US12/986,111 US8329465B2 (en) 1997-06-20 2011-01-06 Recombinant cell clones having increased stability and methods of making and using the same
US14/567,942 USRE46745E1 (en) 1997-06-20 2014-12-11 Recombinant cell clones having increased stability and methods of making and using the same
US15/203,558 USRE46860E1 (en) 1997-06-20 2016-07-06 Recombinant cell clones having increased stability and methods of making and using the same
US15/203,550 USRE46897E1 (en) 1997-06-20 2016-07-06 Recombinant cell clones having increased stability and methods of making and using the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0107397A AT407255B (de) 1997-06-20 1997-06-20 Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons

Publications (2)

Publication Number Publication Date
ATA107397A true ATA107397A (de) 2000-06-15
AT407255B AT407255B (de) 2001-02-26

Family

ID=3506017

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0107397A AT407255B (de) 1997-06-20 1997-06-20 Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons

Country Status (2)

Country Link
US (1) US6100061A (de)
AT (1) AT407255B (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
WO1998008934A1 (en) * 1996-08-30 1998-03-05 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
PL204285B1 (pl) * 2000-02-11 2009-12-31 Bayer Healthcare Llc Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) * 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US20040185534A1 (en) * 2000-10-02 2004-09-23 Knudsen Ida Molgaard Industrial-scale serum-free production of recombinant proteins in mammalian cells
US20040185535A1 (en) * 2003-03-21 2004-09-23 Giles Wilson Industrial-scale serum-free production of recombinant FVII in mammalian cells
AU9165201A (en) * 2000-10-02 2002-04-15 Novo Nordisk As Factor vii glycoforms
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
HUP0402158A2 (hu) * 2001-10-02 2005-01-28 Novo Nordisk Health Care Ag Rekombináns fehérjék előállítási eljárása eukarióta sejtekben
US6825027B2 (en) 2001-12-10 2004-11-30 Baxter Healthcare S.A. Method of production of purified hepatitis a virus particles and vaccine preparation
US6951752B2 (en) 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
US6830917B2 (en) 2001-12-10 2004-12-14 Baxter Healthcare S.A. Method of isolation and purification of trypsin from pronase protease and use thereof
BR0309576A (pt) * 2002-04-30 2005-02-09 Maxygen Holdings Ltd Variante de polipeptìdeo do fator vii (fvii) ou fator viia (fviia), sequência de nucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma variante, e, método para tratar um mamìfero que tenha uma doença ou um distúrbio em que a formação de coágulo é desejável
JP3916516B2 (ja) * 2002-06-10 2007-05-16 独立行政法人科学技術振興機構 硬組織−軟組織界面再生用足場材料
JP2005532057A (ja) * 2002-07-09 2005-10-27 バクスター・インターナショナル・インコーポレイテッド 細胞を培養するための動物性タンパク質非含有培地
UA85543C2 (ru) 2002-09-05 2009-02-10 Бавариан Нордик А/С Способ культивирования первичных клеток и амплификации вирусов в условиях безсывороточной среды, композиция и ее применение, и способ лечения или вакцинации животных
CA2502162C (en) * 2002-09-30 2014-04-15 Bayer Healthcare Llc Fvii or fviia variants having increased clotting activity
CU23097A1 (es) * 2002-10-23 2005-11-18 Centro Inmunologia Molecular Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método
AU2004221761B2 (en) * 2003-03-20 2010-01-07 Bayer Healthcare Llc FVII or FVIIa variants
DE602004025576D1 (de) * 2003-06-19 2010-04-01 Bayer Healthcare Llc Varianten der faktor-vii- oder -viia-gla-domäne
EP1711513B1 (de) 2003-12-01 2014-07-02 Novo Nordisk Health Care AG Nanofiltration von faktor vii lösungen zur entfernung von viren
JP2007515172A (ja) * 2003-12-23 2007-06-14 シェーリング　コーポレイション 無血清培地懸濁培養において安定なａ５４９細胞株を生成するための方法
EP1745141B2 (de) * 2004-05-04 2019-09-25 Novo Nordisk Health Care AG O-verknüpfte glykoformen von faktor vii und verfahren zu deren herstellung
CA2578046A1 (en) * 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
KR20070101227A (ko) 2004-09-07 2007-10-16 아케믹스 코포레이션 폰 빌레브란트 인자에 대한 앱타머 및 이의 혈전증치료제로서의 용도
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
US8530192B2 (en) * 2005-02-11 2013-09-10 Novo Nordisk Healthcare Ag Production of a polypeptide in a serum-free cell culture liquid containing plant protein hydrolysate
US20070231895A1 (en) * 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
CA2633306A1 (en) 2006-01-04 2007-07-12 Baxter International Inc. Oligopeptide-free cell culture media
US8383388B2 (en) * 2006-06-19 2013-02-26 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
AU2008245821B2 (en) 2007-04-26 2013-07-04 Bayer Healthcare Llc Stabilization of liquid solutions of recombinant protein for frozen storage
US20090203766A1 (en) * 2007-06-01 2009-08-13 Archemix Corp. vWF aptamer formulations and methods for use
AU2008345231B2 (en) 2007-12-27 2014-09-11 Takeda Pharmaceutical Company Limited Cell culture processes
CA2716801A1 (en) * 2008-03-12 2009-09-17 Wyeth Llc Methods for identifying cells suitable for large-scale production of recombinant proteins
US20100120093A1 (en) 2008-11-12 2010-05-13 Baxter International Inc. Method of Producing Serum-Free Insulin-Free Factor VII
US8313926B2 (en) 2009-07-31 2012-11-20 Baxter International Inc. Methods for expressing ADAMTS proteins in cell culture medium supplemented with zinc
BR112012006283B1 (pt) 2009-09-21 2022-03-15 Takeda Pharmaceutical Company Limited Formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e, usos de adamts13
PL3626736T3 (pl) 2010-07-08 2025-10-13 Takeda Pharmaceutical Company Limited Sposób wytwarzania rekombinowanego vwf o dużej masie cząsteczkowej w hodowli komórkowej
WO2012023085A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
US8795658B2 (en) 2010-09-17 2014-08-05 Baxter International Inc. Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral pH
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
HUE035941T2 (en) 2011-08-02 2018-05-28 Baxalta GmbH Systems and Methods for Recombinant Production Methods to Increase Protein Yield
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
EP4008768A1 (de) 2013-03-15 2022-06-08 Genzyme Corporation Verfahren zur speicherung hochdichter zellen
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
JP6195191B2 (ja) * 2013-08-08 2017-09-13 極東製薬工業株式会社 無タンパク質・無脂質培地馴化細胞株を用いた組換えタンパク質の製造方法
JP6190205B2 (ja) * 2013-08-08 2017-08-30 極東製薬工業株式会社 無タンパク質・無脂質培地馴化細胞株、その製造方法及び培地
MX383858B (es) 2014-09-18 2025-03-14 Genzyme Corp Métodos de establecimiento de bancos de células de densidad ultra-alta.
EP4127158A2 (de) 2020-04-02 2023-02-08 Takeda Pharmaceutical Company Limited Adamts13-variante, zusammensetzungen und verwendungen davon

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4978616A (en) * 1985-02-28 1990-12-18 Verax Corporation Fluidized cell cultivation process
EP0531562A1 (de) * 1991-09-11 1993-03-17 Doerr, Hans-Wilhelm, Prof. Dr. med. Kultivierung von Säugetierzellen
EP0791055B1 (de) * 1994-11-10 2012-01-25 Baxter Healthcare S.A. Verfahren zur herstellung von biologischen produkten in protein-freier kultur
AU703484B2 (en) * 1995-02-23 1999-03-25 Quest International Services B.V. Peptides for tissue and cell culture media
AUPN442295A0 (en) * 1995-07-26 1995-08-17 Commonwealth Scientific And Industrial Research Organisation Regulated autocrine growth of mammalian cells

Also Published As

Publication number Publication date
US6100061A (en) 2000-08-08
AT407255B (de) 2001-02-26

Similar Documents

Publication Publication Date Title
ATA107397A (de) Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
HUP9900995A3 (en) Artificial stone for stabilising traffic areas in the open
NO20001242D0 (no) April - et nytt protein med veksteffekter
IL130396A0 (en) OB fusion protein compositions and methods
DE69720774D1 (de) S-omeprazol in festform
DK0712862T3 (da) Selektiv acylering af epsilon-aminogrupper i insulin
DE69710487D1 (de) Stabiler standbeutel und verfahren zur herstellung
DK0802941T3 (da) Biologisk nedbrydelige polymerer, fremgangsmåde til fremstilling deraf, samt deres anvendelse til fremstilling af biologisk
HUP9901929A3 (en) New oligomer-organosilane-polisulphanates and their uses in caoutchouc-compounds and for making form bodies
ID18494A (id) Turunan pirazola leburan dan proses pembuatannya
FI952679A7 (fi) Uusia seoksia, menetelmä niiden valmistamiseksi sekä niiden käyttö päällystyksiin
DE69631796D1 (de) Verfahren und zusammensetzung zur reduktion der säure in kaffee
DK0809666T4 (da) Biologisk nedbrydelige polymerer, fremgangsmåder til deres fremstilling samt deres anvendelse til fremstilling af bionedbrydelige formlegemer
DE69703048D1 (de) Glaszusammensetzung, verfahren und verwendung
GB2315752A8 (en) Heat stable anti-freeze proteins
DE69815789D1 (de) Kniegelenkendprothese mit verbesserter hinterer Stabilität und Massnahmen zur Verhinderung einer Dislokation
DE59915087D1 (de) Verfahren zur kontrolle von schadorganismen in kulturen von bt-baumwolle
HUP0003825A2 (en) Method for preparing solution with high chloramine contentration and its use
NO992693L (no) Celledelt radiosystem med forbedrede egenskaper i grenseomrÕder
DE59900960D1 (de) Latentwärmekörper mit porenstruktur und verfahren zu dessen herstellung
FI970097L (fi) Proteiinit, jotka ovat peräisin nisäkkäiden maksasta ja niiden käyttö onkologiassa
IL109717A0 (en) Cell surface proteins and methods for the preparation and use thereof
AU4910299A (en) Gene and protein involved in liver regeneration
DE59805666D1 (de) Aliphatische Alkanale mit verbesserter Lagerstabilität und Verfahren zur Verbesserung der Lagerstabilität
DE59800919D1 (de) Haardauerverformungsverfahren mit zunächst höherem und später niedrigerem pH-Wert in der Reduktionsstufe

Legal Events

Date Code Title Description
MK07 Expiry

Effective date: 20170620